Targeted blocking of miR328 lysosomal degradation with alkalized exosomes sensitizes the chronic leukemia cells to imatinib
暂无分享,去创建一个
Guodong Yang | Yan Dong | Zhuo Wan | Mengying Wei | Guodong Yang | Li Liu | Weiwei Qin | Li Liu | Xiaotong Gao | Yao Lin | Yingxin Zhao | Haotian Wang | Xutao Chen | Xiaotong Gao | Mengying Wei | Z. Wan | Xutao Chen | Yingxin Zhao | Haotian Wang | Yao Lin | W. Qin | Yan Dong | Haotian Wang
[1] G. Daley,et al. Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL , 2003, Cell.
[2] W. Dunn,et al. Autophagy and related mechanisms of lysosome-mediated protein degradation. , 1994, Trends in cell biology.
[3] L. Doyle,et al. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) , 2003, Oncogene.
[4] X. Li,et al. Transcriptional regulation of mammalian miRNA genes. , 2011, Genomics.
[5] Hans Clevers,et al. The cancer stem cell: premises, promises and challenges , 2011, Nature Medicine.
[6] Kathryn A. O’Donnell,et al. c-Myc-regulated microRNAs modulate E2F1 expression , 2005, Nature.
[7] Frank Speleman,et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis , 2010, Nature Cell Biology.
[8] S. Jhanwar,et al. Resistance to imatinib in patients with chronic myelogenous leukemia and the splice variant BCR-ABL1(35INS). , 2016, Leukemia research.
[9] Edurne San José-Enériz,et al. MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations , 2009, Molecular Cancer.
[10] J. Apperley. Chronic myeloid leukaemia , 2015, The Lancet.
[11] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[12] Marilyn E Morris,et al. MicroRNA-328 Negatively Regulates the Expression of Breast Cancer Resistance Protein (BCRP/ABCG2) in Human Cancer Cells , 2009, Molecular Pharmacology.
[13] Quentin Liu,et al. Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation , 2016, Scientific Reports.
[14] Sha Li,et al. Exosome and Exosomal MicroRNA: Trafficking, Sorting, and Function , 2015, Genom. Proteom. Bioinform..
[15] D. Gilliland,et al. Leukemia stem cells. , 2010, Seminars in cancer biology.
[16] P. Doležel,et al. Resistance to daunorubicin, imatinib, or nilotinib depends on expression levels of ABCB1 and ABCG2 in human leukemia cells. , 2014, Chemico-biological interactions.
[17] B. Druker,et al. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. , 2003, Blood.
[18] L. Hu,et al. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant , 2010, British Journal of Cancer.
[19] Tania Nolan,et al. Quantification of mRNA using real-time RT-PCR , 2006, Nature Protocols.
[20] K. Bhalla,et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. , 2007, Blood.
[21] A. Whitehead,et al. The 3′ Untranslated Region of the Membrane-Bound IL-1R Accessory Protein mRNA Confers Tissue-Specific Destabilization , 2004, The Journal of Immunology.
[22] Gunther Hartmann,et al. SiRNA delivery with exosome nanoparticles , 2011, Nature Biotechnology.
[23] Michael R. Green,et al. A therapeutically targetable mechanism of BCR-ABL–independent imatinib resistance in chronic myeloid leukemia , 2014, Science Translational Medicine.
[24] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[25] M. Noble,et al. Cancer stem cells. , 2006, The New England journal of medicine.
[26] H. Grosshans,et al. MicroRNA turnover: when, how, and why. , 2012, Trends in biochemical sciences.
[27] A. van den Berg,et al. MicroRNAs, macrocontrol: regulation of miRNA processing. , 2010, RNA.
[28] H. Kantarjian,et al. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy , 2012, Cancer.
[29] B. Druker,et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. , 2011, The Journal of clinical investigation.
[30] J. Melo,et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. , 2003, Blood.
[31] G. Hannon,et al. A MicroRNA Feedback Circuit in Midbrain Dopamine Neurons , 2007, Science.
[32] A. Hata,et al. Regulation of MicroRNA Biogenesis: A miRiad of mechanisms , 2009, Cell Communication and Signaling.
[33] F. Sánchez‐Madrid,et al. ISGylation controls exosome secretion by promoting lysosomal degradation of MVB proteins , 2016, Nature Communications.
[34] K. Wada,et al. Lysosomal putative RNA transporter SIDT2 mediates direct uptake of RNA by lysosomes , 2016, Autophagy.
[35] T. Litman,et al. Regulation of ABCG2 Expression at the 3′ Untranslated Region of Its mRNA through Modulation of Transcript Stability and Protein Translation by a Putative MicroRNA in the S1 Colon Cancer Cell Line , 2008, Molecular and Cellular Biology.
[36] Eeva-Liisa Eskelinen,et al. Autophagy: a lysosomal degradation pathway with a central role in health and disease. , 2009, Biochimica et biophysica acta.
[37] Guodong Yang,et al. Semi-random mutagenesis profile of BCR-ABL during imatinib resistance acquirement in K562 cells , 2017, Molecular medicine reports.
[38] W. Filipowicz,et al. The widespread regulation of microRNA biogenesis, function and decay , 2010, Nature Reviews Genetics.
[39] I. Cascorbi,et al. MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression , 2012, Pharmacogenetics and genomics.
[40] M. Talpaz,et al. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia , 2011, Leukemia.
[41] Tsung-Cheng Chang,et al. Widespread microRNA repression by Myc contributes to tumorigenesis , 2008, Nature Genetics.
[42] B. Aggarwal,et al. Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia , 2004, Cancer Research.
[43] S. Emr,et al. Autophagy as a regulated pathway of cellular degradation. , 2000, Science.
[44] J. Radich,et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. , 2008, Blood.
[45] M. Dean,et al. Multidrug Efflux Pumps and Cancer Stem Cells: Insights Into Multidrug Resistance and Therapeutic Development , 2011, Clinical pharmacology and therapeutics.
[46] K. Wada,et al. Lysosomal degradation of intracellular nucleic acids-multiple autophagic pathways. , 2016, Journal of biochemistry.
[47] M. Fabbri,et al. MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications , 2008, Leukemia.
[48] M. Caligiuri,et al. miR-328 Functions as an RNA Decoy to Modulate hnRNP E2 Regulation of mRNA Translation in Leukemic Blasts , 2010, Cell.
[49] J. Visvader,et al. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.